Clinical trials: Metastatic Progressive Castration-resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
The purpose of this study was to assess the efficacy, safety, tolerability, Pharmacokinetic(s) (PK) and dosimetry of [177Lu]Lu-PSMA-617 when administered in addition to Best Supportive/Best Standard of Care (BSC/BSoC) in Chinese…
- Trial name
- NCT05670106
- Testing
- [177Lu]Lu-PSMA-617, Best supportive/best standard of care (BS/BSOC), 68Ga-PSMA-11
- Where
- 17 sites in China
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.
- Trial name
- NCT00479635
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cortice Biosciences, Inc.
Prostate Cancer
Radium-223 in Combination With Enzalutamide
This study aims to determine the safety and tolerability of Radium-223 when administered in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
- Trial name
- NCT02225704
- Testing
- Radium-223 and enzalutamide
- Where
- 7 sites in Ireland
- Volunteers
- 45 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing
The aim of this retrospective study was to assess the prognostic value of parameters extracted from 18FDG PET/CT and 68Ga-PSMA PET in the initial workup and follow-up of patients treated with 177Lu-PSMA in mCRPC.
- Trial name
- PROFLu (NCT06460454)
- Testing
- PET scan of 18F-FDG
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Prostate Cancer
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer.
- Trial name
- NCT01171898
- Testing
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
This research study is being done to measure the clinical benefit of TRC105 in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or…
- Trial name
- NCT03418324
- Testing
- TRC105, Abiraterone, Enzalutamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Prostate Cancer
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
This study will investigate the safety and efficacy of Sacituzumab Govitecan in patients with metastatic castration-resistant prostate cancer progressing on second generation androgen receptor (AR) directed therapy (e.g.…
- Trial name
- NCT03725761
- Testing
- Sacituzumab Govitecan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with…
- Trial name
- NCT07795268
- Testing
- 177Lu-NYM032 injection, Best supportive/best standard of care
- Volunteers
- 600 people
- Sponsor
- Norroy Bioscience Co., LTD
Progressive Metastatic Castrate Resistant Prostate Cancer
Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib
The dosage of trametinib for oral administration is 2mg once daily. The patient is instructed to take the trametinib oncedaily dose at approximately the same time each day, by mouth with approximately 200 mL (almost 1 cup) of…
- Trial name
- NCT03386071
- Testing
- Trametinib 2 mg
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Background: Some prostate cancer keeps growing even when testosterone in the body drops to very low levels. This is called castrate-resistant prostate cancer. One treatment is enzalutamide. This is a modern hormonal therapy.
- Trial name
- NCT03531827
- Testing
- enzalutamide, CRLX101
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor…
- Trial name
- NCT07567521
- Testing
- Radiopharmaceuticals
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- C Ray Therapeutics
Prostate Cancer
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated machine vision based image analysis of…
- Trial name
- NCT00578409
- Where
- United States
- Volunteers
- 758 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well trametinib works in treating patients with hormone-resistant prostate cancer that is growing or getting worse and has spread to other parts of the body.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT02881242
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Trametinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
- Trial name
- DUAL-NK-PC (NCT07641049)
- Testing
- ETB-DualNK-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Prostate Cancer
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
The main object of this multicenter, randomized, double-blind, placebo-controlled phase III trial is to assess impact of maintenance of orteronel on disease progression and hence on quality of life of patients with metastatic…
- Trial name
- NCT02053311
- Testing
- Orteronel
- Where
- 7 sites in Switzerland
- Sponsor
- Swiss Cancer Institute
Prostate Cancer
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy…
- Trial name
- NCT04946370
- Testing
- 225Ac-J591, Pembrolizumab, Androgen receptor inhibitor
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have progressive…
- Trial name
- NCT00005848
- Testing
- chemotherapy, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Progressive Castration-resistant Prostate Cancer
Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide
This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to…
- Trial name
- NCT01091103
- Testing
- Enzalutamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Prostate Cancer
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591, that can be given without severe side effects.
- Trial name
- NCT04506567
- Testing
- Multiple Dose of 225Ac-J591 at 45 KBq/kg, Multiple Dose of 225Ac-J591 at 55 KBq/kg, Multiple Dose of 225Ac-J591 at 65 KBq/kg
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
This is a phase I dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA small molecule. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates…
- Trial name
- NCT04886986
- Testing
- 225Ac-J591, 177Lu-PSMA-617, 68Ga-PSMA-11
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Weill Medical College of Cornell University